UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 27, 2016
Seattle Genetics, Inc.
(Exact name of Registrant as specified in its charter)
| | | | |
| Delaware | | 0-32405 | | 91-1874389 |
(State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
21823 30th Drive SE
Bothell, Washington 98021
(Address of principal executive offices, including zip code)
(425)527-4000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Item 8.01 Other Events.
On December 27, 2016, Seattle Genetics, Inc. (the “Company”) issued a press release announcing a clinical hold on several Phase 1 trials of vadastuximab talirine(SGN-CD33A). The Company’s press release is attached as Exhibit 99.1 to this current report and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| | |
| 99.1 | | Press Release of Seattle Genetics, Inc. dated December 27, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | SEATTLE GENETICS, INC. |
| | | |
| Date: December 27, 2016 | | | | By: | | /s/ Clay B. Siegall |
| | | | | | Clay B. Siegall President and Chief Executive Officer |
INDEX TO EXHIBITS
| | |
Exhibit
No. | | Description |
| |
| 99.1 | | Press Release of Seattle Genetics, Inc. dated December 27, 2016 |
